CN108251374A - 一种人急性b淋巴细胞白血病细胞株及其应用 - Google Patents
一种人急性b淋巴细胞白血病细胞株及其应用 Download PDFInfo
- Publication number
- CN108251374A CN108251374A CN201810074129.5A CN201810074129A CN108251374A CN 108251374 A CN108251374 A CN 108251374A CN 201810074129 A CN201810074129 A CN 201810074129A CN 108251374 A CN108251374 A CN 108251374A
- Authority
- CN
- China
- Prior art keywords
- people
- cell strain
- cell
- acute
- lineage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 title claims abstract description 122
- 208000032839 leukemia Diseases 0.000 title claims abstract description 43
- 230000001154 acute effect Effects 0.000 title claims abstract description 40
- 210000004698 lymphocyte Anatomy 0.000 title claims abstract description 37
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims abstract description 21
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims abstract description 21
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims abstract description 19
- 230000007246 mechanism Effects 0.000 claims abstract description 16
- 238000011160 research Methods 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 9
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 238000012216 screening Methods 0.000 claims description 3
- 238000010171 animal model Methods 0.000 claims description 2
- 238000011604 leukemia animal model Methods 0.000 abstract description 5
- 238000012827 research and development Methods 0.000 abstract description 4
- 238000007877 drug screening Methods 0.000 abstract description 3
- 230000008506 pathogenesis Effects 0.000 abstract description 3
- 238000009509 drug development Methods 0.000 abstract description 2
- 230000002906 microbiologic effect Effects 0.000 abstract description 2
- 239000002547 new drug Substances 0.000 abstract description 2
- 102100022103 Histone-lysine N-methyltransferase 2A Human genes 0.000 abstract 1
- 101001045846 Homo sapiens Histone-lysine N-methyltransferase 2A Proteins 0.000 abstract 1
- 230000012010 growth Effects 0.000 description 18
- 238000011081 inoculation Methods 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 210000001185 bone marrow Anatomy 0.000 description 9
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- 238000005138 cryopreservation Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 238000011579 SCID mouse model Methods 0.000 description 4
- 230000022131 cell cycle Effects 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000013394 immunophenotyping Methods 0.000 description 3
- 210000005087 mononuclear cell Anatomy 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000005034 decoration Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000012268 genome sequencing Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 102000007325 Amelogenin Human genes 0.000 description 1
- 108010007570 Amelogenin Proteins 0.000 description 1
- 102100022749 Aminopeptidase N Human genes 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 208000025321 B-lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 101100115215 Caenorhabditis elegans cul-2 gene Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 108010022894 Euchromatin Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 206010062489 Leukaemia recurrent Diseases 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- 108090000028 Neprilysin Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 210000000632 euchromatin Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 238000006902 nitrogenation reaction Methods 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 208000017426 precursor B-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/5052—Cells of the immune system involving B-cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
- C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/12—Animals modified by administration of exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- General Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pathology (AREA)
- Environmental Sciences (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
患者骨髓 | HXEX-ALL1 | |
Amelogenin | X,Y | X,Y |
CSF1PO | 11,13 | 11,13 |
D13S317 | 11,11 | 11,11 |
D16S539 | 10,11 | 10,11 |
D5S818 | 7,10 | 7,10 |
D7S820 | 10,12 | 10,12 |
TH01 | 9,9 | 9,9 |
TPOX | 8,9 | 8,9 |
vWA | 16,17 | 16,17 |
Penta E | 5,19 | 5,19 |
Penta D | 9,11 | 9,11 |
D2S441 | 11,11.3 | 11,11.3 |
D2S1338 | 18,24 | 18,24 |
D3S1358 | 15,15 | 15,15 |
D6S1043 | 12,19 | 12,19 |
D8S1179 | 13,15 | 13,15 |
D10S1248 | 13,14 | 13,14 |
D12S391 | 18,20 | 18,20 |
D18S51 | 13,23 | 13,23 |
D19S433 | 14,15 | 14,15 |
D21S11 | 29,33 | 29,33 |
FGA | 24,26 | 24,26 |
抗原(CD) | 患者初诊 | HXEX-ALL1 |
B系标记 | ||
CD10 | 阳性 | 阳性 |
CD19 | 阳性 | 阳性 |
CD20 | 阴性 | 阴性 |
CD22 | 阳性 | 阳性 |
cCD79a | 阳性 | 阳性 |
cIgM | 阴性 | 阴性 |
sIgM | 阴性 | 阴性 |
T系标记 | ||
CD2 | 阴性 | 阴性 |
CD3 | 阴性 | 阴性 |
CD5 | 阳性 | 阳性 |
CD7 | 阴性 | 阴性 |
cCD3 | 阴性 | 阴性 |
髓系标记 | ||
CD13 | 阴性 | 阴性 |
CD33 | 阴性 | 阴性 |
CD117 | 阴性 | 阴性 |
其他 | ||
CD34 | 部分阳性 | 阴性 |
HLA-DR | 阳性 | 阳性 |
Claims (7)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810074129.5A CN108251374B (zh) | 2018-01-25 | 2018-01-25 | 一种人急性b淋巴细胞白血病细胞株及其应用 |
PCT/CN2018/107556 WO2019144636A1 (zh) | 2018-01-25 | 2018-09-26 | 一种人急性b淋巴细胞白血病细胞株及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810074129.5A CN108251374B (zh) | 2018-01-25 | 2018-01-25 | 一种人急性b淋巴细胞白血病细胞株及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108251374A true CN108251374A (zh) | 2018-07-06 |
CN108251374B CN108251374B (zh) | 2019-02-12 |
Family
ID=62742704
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810074129.5A Active CN108251374B (zh) | 2018-01-25 | 2018-01-25 | 一种人急性b淋巴细胞白血病细胞株及其应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN108251374B (zh) |
WO (1) | WO2019144636A1 (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019144636A1 (zh) * | 2018-01-25 | 2019-08-01 | 四川大学华西第二医院 | 一种人急性b淋巴细胞白血病细胞株及其应用 |
CN110699324A (zh) * | 2019-11-25 | 2020-01-17 | 四川大学华西第二医院 | 一种小鼠成纤维细胞肿瘤细胞株及其应用 |
CN111118099A (zh) * | 2018-10-30 | 2020-05-08 | 启迪汉洱康(嘉兴)生物科技有限公司 | 一种用于白血病高通量药物筛查的方法 |
CN112877290A (zh) * | 2021-03-04 | 2021-06-01 | 浙江大学 | 一种人t淋巴母细胞白血病/淋巴瘤细胞株及其应用 |
CN113337470A (zh) * | 2021-03-05 | 2021-09-03 | 上海交通大学医学院附属新华医院 | 一种人源皮肤白血病的pdx模型细胞和应用 |
CN114457017A (zh) * | 2022-01-19 | 2022-05-10 | 四川大学华西第二医院 | 一种小鼠成纤维细胞肿瘤细胞株HXLyAF-KBM及其应用 |
CN114703138A (zh) * | 2022-02-09 | 2022-07-05 | 四川大学华西第二医院 | 一种淋巴结来源淋巴瘤相关成纤维细胞肿瘤细胞株及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104498435A (zh) * | 2014-12-15 | 2015-04-08 | 中国科学院广州生物医药与健康研究院 | 一种原代b细胞急性淋系白血病细胞的体外培养方法 |
CN105821002A (zh) * | 2016-02-16 | 2016-08-03 | 复旦大学附属华山医院 | 伴有add(11)(q23)染色体异常的高侵袭性人急性B淋巴细胞白血病细胞株 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108251374B (zh) * | 2018-01-25 | 2019-02-12 | 四川大学华西第二医院 | 一种人急性b淋巴细胞白血病细胞株及其应用 |
-
2018
- 2018-01-25 CN CN201810074129.5A patent/CN108251374B/zh active Active
- 2018-09-26 WO PCT/CN2018/107556 patent/WO2019144636A1/zh active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104498435A (zh) * | 2014-12-15 | 2015-04-08 | 中国科学院广州生物医药与健康研究院 | 一种原代b细胞急性淋系白血病细胞的体外培养方法 |
CN105821002A (zh) * | 2016-02-16 | 2016-08-03 | 复旦大学附属华山医院 | 伴有add(11)(q23)染色体异常的高侵袭性人急性B淋巴细胞白血病细胞株 |
Non-Patent Citations (1)
Title |
---|
朱玲英: "纳米银对小鼠骨髓来源pro-B细胞的作用研究", 《东南大学硕士学位论文》 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019144636A1 (zh) * | 2018-01-25 | 2019-08-01 | 四川大学华西第二医院 | 一种人急性b淋巴细胞白血病细胞株及其应用 |
CN111118099A (zh) * | 2018-10-30 | 2020-05-08 | 启迪汉洱康(嘉兴)生物科技有限公司 | 一种用于白血病高通量药物筛查的方法 |
CN110699324A (zh) * | 2019-11-25 | 2020-01-17 | 四川大学华西第二医院 | 一种小鼠成纤维细胞肿瘤细胞株及其应用 |
CN110699324B (zh) * | 2019-11-25 | 2021-05-11 | 四川大学华西第二医院 | 一种小鼠成纤维细胞肿瘤细胞株及其应用 |
CN112877290A (zh) * | 2021-03-04 | 2021-06-01 | 浙江大学 | 一种人t淋巴母细胞白血病/淋巴瘤细胞株及其应用 |
CN112877290B (zh) * | 2021-03-04 | 2021-11-30 | 浙江大学 | 一种人t淋巴母细胞白血病/淋巴瘤细胞株及其应用 |
CN113337470A (zh) * | 2021-03-05 | 2021-09-03 | 上海交通大学医学院附属新华医院 | 一种人源皮肤白血病的pdx模型细胞和应用 |
CN113337470B (zh) * | 2021-03-05 | 2022-08-02 | 上海交通大学医学院附属新华医院 | 一种人源皮肤白血病的pdx模型细胞和应用 |
CN114457017A (zh) * | 2022-01-19 | 2022-05-10 | 四川大学华西第二医院 | 一种小鼠成纤维细胞肿瘤细胞株HXLyAF-KBM及其应用 |
CN114457017B (zh) * | 2022-01-19 | 2023-10-17 | 四川大学华西第二医院 | 一种小鼠成纤维细胞肿瘤细胞株HXLyAF-KBM及其应用 |
CN114703138A (zh) * | 2022-02-09 | 2022-07-05 | 四川大学华西第二医院 | 一种淋巴结来源淋巴瘤相关成纤维细胞肿瘤细胞株及其应用 |
CN114703138B (zh) * | 2022-02-09 | 2023-07-07 | 四川大学华西第二医院 | 一种淋巴结来源淋巴瘤相关成纤维细胞肿瘤细胞株及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN108251374B (zh) | 2019-02-12 |
WO2019144636A1 (zh) | 2019-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108251374B (zh) | 一种人急性b淋巴细胞白血病细胞株及其应用 | |
CN103627673A (zh) | 一种人脑胶质瘤细胞系及其建立方法和应用 | |
CN104894065A (zh) | 一种nk细胞培养基及nk细胞的培养方法 | |
CN104694476A (zh) | 一种人非小细胞肺癌细胞系及其建立方法和应用 | |
CN102988415B (zh) | 人异基因有核细胞工业化制备自然杀伤性细胞(nk)及注射液 | |
CN105255832A (zh) | 一种人胆管癌细胞系及其应用 | |
CN110106150A (zh) | 一种滑膜肉瘤细胞系hSS-005R的制备方法及应用 | |
CN104195109A (zh) | 一种人肺腺癌细胞系及其应用 | |
Low et al. | Viability of Escherichia coli ATCC 8739 in nutrient broth, luria-bertani broth and brain heart infusion over 11 weeks | |
CN105062969B (zh) | 一种提高脐带血巨核祖细胞体外诱导分化效率的方法 | |
CN102604895B (zh) | 一种人原代肿瘤细胞分离与培养试剂盒 | |
CN110055219B (zh) | 一种利用非动员外周血制备异质性造血干祖细胞的方法 | |
US20230076866A1 (en) | Human t-lymphoblastic leukemia/lymphoma cell strain and use thereof | |
CN116832062A (zh) | 一种小分子抑制剂药物增强nk细胞抗肿瘤作用的用途及其应用 | |
CN103509101A (zh) | 一种扩增脐带血造血干细胞的细胞因子及其培养基 | |
CN102876632B (zh) | 人nk/t细胞系 | |
CN110305844A (zh) | 一种鲫鱼脊髓组织细胞系及其应用 | |
CN103667192B (zh) | 一种人不典型慢性粒细胞性白血病细胞株及其制备方法 | |
CN107460171A (zh) | 人甲状腺未分化癌细胞系及其应用 | |
CN104403996B (zh) | 一种具有5-氟尿嘧啶耐药性的人胃癌细胞系及其建立方法和应用 | |
CN110438081B (zh) | 人套细胞淋巴瘤恶性克隆细胞株及其建立方法和应用 | |
CN104419676A (zh) | hTERT基因重组构建唐氏综合征细胞模型及其细胞库 | |
CN110172448A (zh) | 一种滑膜肉瘤细胞系hSS-005R及其子代细胞系 | |
CN109486767B (zh) | 一种人上皮性卵巢癌细胞shov4及其应用 | |
CN106520695A (zh) | 含参附多糖的促cik细胞增殖分化的添加剂、培养基、培养方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Gu Ling Inventor after: Zhu Yiping Inventor after: Zhang Ge Inventor after: Yang Rong Inventor after: Zhang Yanle Inventor after: Zhang Shuwen Inventor before: Gu Ling Inventor before: Zhu Yiping Inventor before: Zhang Ge Inventor before: Yang Rong Inventor before: Zhang Yanle Inventor before: Sun Shuwen |
|
CB03 | Change of inventor or designer information | ||
GR01 | Patent grant | ||
GR01 | Patent grant |